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The major causes of mortality, and a great deal of morbidity, are cardiovascular disease and 
cancer. The endothelium, reputed to be the largest organ in the body (weighing about a 
kilogram and consisting of some 1-6 x1013 cells (1), is undoubtedly the primary target for the 
disease process of atherosclerosis (2). Epidemiological studies such as the Framingham Heart 
Study and others have unequivocally defined the importance of the four major risk factors for 
this disease. Their pathological link is that, either directly or indirectly, each of the risk 
factors independently cause damage to the endothelium, and of course in a clinical setting 
they overlap as, for example, many diabetics also have hypertension and dyslipidaemia (3). 
As regards cancer, the endothelium is important because of its role in angiogenesis (4). 
Furthermore, the endothelium is sensitive to cytotoxic chemotherapy, and this is perhaps why 
some forms of chemotherapy are successful in that they preferentially destroy those blood 
vessels feeding a tumour. In both disease groups a damaged endothelium loses its 
anticoagulant nature and becomes procoagulant, thereby providing a link with 
atherothrombosis in cardiovascular disease, and potentially with the increased risk of venous 
thromboembolism in cancer (especially during bolus chemotherapy)(5). A malfunctioning 
endothelium is unable to part-regulate blood pressure, leading to hypertension. Loss of the 
barrier function of the endothelium seem likely to be a contributor to oedema, whilst the 
increased expression of adhesion molecules (such as intercellular adhesion molecule [ICAM] 
and E selectin which recruit leukocytes) and release of cytokines such as IL-6 are likely 
contributors to inflammation (6,7). Consequently, the endothelium is of great interest to 
oncologists, cardiologists and hematologists, all of whom are keen to develop methods of 
assessing the integrity of this tissue. Candidate methods include those of plasma markers, 
techniques based on blood flow, and of cell biology. 
 
The endothelium secretes and/or releases and/or expresses at its cell surface a variety of 
molecules (table 1). These molecules have a variety of functions, such as contributing to the 
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regulation of hemostasis (when released or expressed luminally) and to vascular tone (when 
released into the vessel wall), some of which act as antagonistic pairs (7). Furthermore, 
several are easily measured in plasma by immunoassay, although not all are specific products 
of the endothelium. Endothelial integrity may also be assessed by changes in vascular tone, 
hypertension being a classic model, although endothelial-independent smooth muscle cell 
change may also be important in this disease. Nonetheless, endothelial function can be 
determined in a physiological setting by techniques such as flow mediated dilatation and 
arterial stiffness/pulse wave velocity, although these methods are slow and are strongly 
operator dependent (8-10).  
 
The healthy endothelium adheres to the internal elastic lamina of the intima until it dies or is 
driven off by a disease process, at which time cells may the found in the plasma: hence 
circulating endothelial cells (CECs). Although described long ago (11,12), research on CECs 
took off once specific markers, such as CD146, were discovered (13). Thus armed, increased 
numbers of CECs were described in many cardiovascular, inflammatory and neoplastic 
diseases, the interpretation being that each disease process was (at least) partly responsible 
for this increase (14-16). However, others used alternative molecules to define CECs (17), 
and further confusion followed from the parallel discovery of bone marrow derived 
endothelial progenitor cells (EPCs), said to be a population that replaced the dead and dying 
CECs (18). Further confusion followed with the use of additional markers (many of which are 
expressed by non-endothelial cells (table 2)) such as CD34 and CD309 (19,20), and the use of 
intimately linked terms such as ‘circulating progenitor cell’ and ‘endothelial progenitor cells’, 
alone and in combination (21). The most recent development in this area is of endothelial 
microparticles (EMPs), exceptionally small particles of cytoplasm, increased numbers of 
which are, like CECs and plasma markers, increased in cardiovascular disease (22,23). 
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Schmidt et al have accurately summarised these issues in the present volume of the Journal 
(24). 
Having agreed that the endothelium is an important organ/tissue whose status needs to be 
accessed, how should this be achieved? Clearly one of the more important arteries (if not the 
most important artery) is that of the epicardium, upon which the beating heart relies. 
Reminiscent of Koch’s postulate for pathogenic organisms, Flammer et al (25), focussing on 
the heart, described nine criteria for an optimal endothelial function test, these being that it 
reflects the disease state, is reversible with interventions, mirrors coronary endothelial 
function, improves risk stratification, is reproducible, is operator independent, is non-invasive 
(with no or low risk for the patient), is easy to use and is inexpensive. Table 3 sets these nine 
criteria, and others, against a cross-section of methods (26). It is clear that none of the 
methods (as yet) comes anywhere near close to being a truly useful method, in the same way 
are the full blood count, urea and electrolytes and the electrocardiogram, for assessing 
coronary endothelial function. However, any of these methods may be useful in determining 
the state of other vascular systems, such as those of the brain. But in considering wider 
pathophysiological issues, an alternative use of these methods may be in determining global 
endothelial function and damage, and this may be important in other settings such as 
disseminated intravascular coagulation or in septicemia (27-30). 
 
So using one or more of these tests, suppose we have identified a patient at high risk of an 
adverse cardiovascular event by virtue of poor endothelial function – how should we 
proceed? Inasmuch as the four major risk factors are cytotoxic to the endothelium, and that 
reversal of the factors restores endothelial integrity, then the strategy is clear. However, the 
process of treating the risk factors for atherosclerosis, whether by formal pharmaceutical 
intervention (statins, ACE inhibitors, hypoglycemics) or by simply adopting a healthy 
lifestyle (no smoking, a diet rich in fresh fruit and vegetables, regular exercise, avoidance of 
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overweight and obesity) has been known for decades as effective in reducing major 
cardiovascular events (31,32). Furthermore, vascular dysfunction is not the only 
pathophysiology that contributes to atherosclerosis. Suppression of platelet function by 
aspirin in probably the most successful single cardiovascular intervention of the 20th century, 
and in addition reversal of the risk factors is also likely to reduce inappropriate platelet and 
coagulation activation independently of any effect on the endothelium (33,34).  
 
Clinical research is as sensitive to Darwinian mechanisms as any other field: our area of study 
is littered with disappointments, an excellent example being the hope of using viral plasmid 
as therapeutics (35). Similarly, endothelial progenitor cells have (as yet) not translated from 
the laboratory to the bedside (36), although more time may be needed. Two decades ago, I 
speculated that plasma markers may be useful in some settings, whilst a decade ago, Hwa et 
al drew attention to a bench-to-beside gap that has still to be closed (37,38). Although plasma 
von Willebrand factor adds to risk-factor scores for predicting outcome in atrial fibrillation 
(39), and despite its ease of measurement, much more work is required before even this one 
molecule is adopted as a routine laboratory marker. Although a daunting task, the 
introduction into routine pathology of brain naturietic peptide as marker of heart failure 
provides a model (40). However, perhaps our focus on one single marker is short-sighted. 
With an organ as complex and widespread as the endothelium perhaps a panel of markers 
representing different aspects of vascular physiology and pathology may be fruitful (7,41). 
Such a panel may well include CECs and/or endothelial microparticles as Schmidt and 
colleagues promote (24), but much work needs to be done, especially in the adoption of an 
international consensus on methodology. 
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Table 1: Products of the endothelium 
 
Anti-coagulant/vasorelaxive 
Anti-inflammatory 
 
 
Pro-coagluant/vascoconstrictive 
Pro-inflammatory 
 
Nitric oxide 
 
 
Endothelin 
 
Prostacyclin 
 
 
Thromboxane 
 
Tissue plasminogen activator 
 
 
Plasminogen activator inhibitor 
 
Protein C 
 
 
Tissue factor 
 
Heparin 
 
 
Von Willebrand factor 
 
Thrombomodulin 
 
 
Factor V 
 
 
 
 
Interleukins/cytokines 
 
 
 
 
Adhesion molecules 
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Table 2:  Endothelial markers and their 
expression on non-endothelial cells 
 
 
Marker 
 
 
Antigen name 
 
Expression on non-
endothelial cells 
 
PECAM-1 
 
CD31 Platelets, leucocytes 
ICAM-1 
 
CD54 Leucocytes 
Endoglin 
 
CD105 Macrophages, activated 
monocytes, erythroid 
progenitors, pre-B 
lymphocytes 
VCAM-1 
 
CD106 Stromal cells, smooth muscle 
cells, fibroblasts 
Thrombomodulin 
 
CD141 Platelets, monocytes, 
neutrophils, keratinocytes 
E-cadherin 
 
CD144 Fetal liver cells 
P1H12, S-endo-1 
 
 
CD146 pericytes, bone marrow 
fibroblasts, nerve fibres, 
activated T-lymphocyte, 
malignant cells 
VEGF receptor 1, KDR 
 
CD309 Hematopoietic cells, 
progenitor cells 
von Willebrand factor  
 
Platelets 
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Table 3: Criteria for an Optimal Endothelial Function Test 
 
 
Criterion 
 
Plasma 
markers
* 
 
CECs 
 
EMPs 
 
FMD 
 
PWV/AS 
 
Coronary 
epicardial  
vasoreactivit
y 
Reflects 
disease state 
Probably Possibly Possibly Probably Probably Yes 
Reversible 
with 
interventions 
Yes Unclear, 
probably 
Possibly Yes Probably Yes 
Reflects 
coronary 
endothelial 
function 
No No No Indirectly Possibly Yes  
(Gold 
Standard) 
Improves risk 
stratification 
Possibly Unclear Possibly Possibly Possibly Probably 
Reproducibilit
y 
Good Poor Moderate 
/poor 
Moderate Moderate Moderate 
Operator 
independent 
Yes Yes Yes No No No 
Invasive No No No No (but 
inconvenien
t 
No Very 
Easy to use Yes No No No No No 
Inexpensive Yes No No No No No 
Consensus on 
definition 
Yes Weak Weak Yes Yes Yes 
Consensus on 
method 
Yes No Weak Modest Modest Yes 
Potential as a  
Global marker 
Yes Yes Yes Possibly Possibly No 
 
*for example, von Willebrand factor, soluble thrombomodulin. CECs = circulating 
endothelial cells, EMPS = endothelial microparticles, FMD = flow mediated dilatation, 
PWV/AS = pulse wave velocity/ arterial stiffness. 
 
 
 
 
